Acrivon Therapeutics Inc
ACRV2.160USD
-0.100-4.42%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
68.15MMarket Cap
LossP/E TTM
More Details of Acrivon Therapeutics Inc Company
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Acrivon Therapeutics Inc Info
Ticker SymbolACRV
Company nameAcrivon Therapeutics Inc
IPO dateNov 15, 2022
CEOBlume-Jensen (Peter)
Number of employees75
Security typeOrdinary Share
Fiscal year-endNov 15
Address480 Arsenal Way, Suite 100
CityWATERTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02472
Phone16172078979
Websitehttps://acrivon.com/
Ticker SymbolACRV
IPO dateNov 15, 2022
CEOBlume-Jensen (Peter)
Company Executives of Acrivon Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Peter Blume-Jensen, M.D., Ph.D.
Dr. Peter Blume-Jensen, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.17M
-0.91%
Dr. Kristina Masson, Ph.D.
Dr. Kristina Masson, Ph.D.
Executive Vice President - Business Operations, Director
Executive Vice President - Business Operations, Director
316.18K
-0.34%
Dr. Eric Devroe, Ph.D.
Dr. Eric Devroe, Ph.D.
Chief Operating Officer
Chief Operating Officer
65.31K
-0.93%
Dr. Erick Gamelin, M.D., Ph.D.
Dr. Erick Gamelin, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
15.28K
-2.57%
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mrs. Mary-Alice Miller, J.D.
Mrs. Mary-Alice Miller, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
--
-100.00%
Dr. Charles M. Baum, M.D., Ph.D.
Dr. Charles M. Baum, M.D., Ph.D.
Independent Director
Independent Director
--
-100.00%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Peter Blume-Jensen, M.D., Ph.D.
Dr. Peter Blume-Jensen, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.17M
-0.91%
Dr. Kristina Masson, Ph.D.
Dr. Kristina Masson, Ph.D.
Executive Vice President - Business Operations, Director
Executive Vice President - Business Operations, Director
316.18K
-0.34%
Dr. Eric Devroe, Ph.D.
Dr. Eric Devroe, Ph.D.
Chief Operating Officer
Chief Operating Officer
65.31K
-0.93%
Dr. Erick Gamelin, M.D., Ph.D.
Dr. Erick Gamelin, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
15.28K
-2.57%
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
--
-100.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
26.43%
Chione, Ltd.
12.20%
Blume-Jensen (Peter)
6.87%
Sands Capital Ventures LLC
6.73%
Citadel Advisors LLC
5.46%
Other
42.32%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
26.43%
Chione, Ltd.
12.20%
Blume-Jensen (Peter)
6.87%
Sands Capital Ventures LLC
6.73%
Citadel Advisors LLC
5.46%
Other
42.32%
Shareholder Types
Shareholders
Proportion
Venture Capital
26.55%
Hedge Fund
16.43%
Corporation
12.20%
Individual Investor
8.36%
Investment Advisor
6.86%
Investment Advisor/Hedge Fund
5.00%
Research Firm
1.28%
Other
23.33%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
134
17.71M
69.32%
+182.87K
2025Q3
137
17.53M
70.68%
-320.02K
2025Q2
135
17.85M
68.05%
-1.81M
2025Q1
131
22.63M
79.77%
-2.38M
2024Q4
129
23.33M
79.05%
+324.92K
2024Q3
114
23.28M
78.63%
-499.83K
2024Q2
109
23.78M
71.37%
+2.33M
2024Q1
99
15.56M
68.24%
+116.36K
2023Q4
85
15.61M
68.75%
+202.59K
2023Q3
80
15.41M
69.26%
-33.48K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
8.34M
26.52%
--
--
Jun 30, 2025
Chione, Ltd.
3.85M
12.24%
--
--
Jun 30, 2024
Blume-Jensen (Peter)
2.19M
6.95%
-19.91K
-0.90%
Aug 21, 2025
Sands Capital Ventures LLC
2.12M
6.75%
--
--
Jun 30, 2025
Citadel Advisors LLC
1.90M
6.03%
--
--
Jun 30, 2025
Wellington Management Company, LLP
888.13K
2.82%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
593.25K
1.89%
-81.54K
-12.08%
Jun 30, 2025
Renaissance Technologies LLC
509.30K
1.62%
+457.19K
+877.53%
Jun 30, 2025
Two Sigma Investments, LP
213.77K
0.68%
+213.77K
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Nasdaq Biotechnology ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
iShares Biotechnology ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
Schwab U.S. Broad Market ETF
0%
View more
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
iShares Micro-Cap ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Biotechnology ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Acrivon Therapeutics Inc?
The top five shareholders of Acrivon Therapeutics Inc are:
RA Capital Management, LP holds 8.34M shares, accounting for 26.52% of the total shares.
Chione, Ltd. holds 3.85M shares, accounting for 12.24% of the total shares.
Blume-Jensen (Peter) holds 2.19M shares, accounting for 6.95% of the total shares.
Sands Capital Ventures LLC holds 2.12M shares, accounting for 6.75% of the total shares.
Citadel Advisors LLC holds 1.90M shares, accounting for 6.03% of the total shares.
RA Capital Management, LP holds 8.34M shares, accounting for 26.52% of the total shares.
Chione, Ltd. holds 3.85M shares, accounting for 12.24% of the total shares.
Blume-Jensen (Peter) holds 2.19M shares, accounting for 6.95% of the total shares.
Sands Capital Ventures LLC holds 2.12M shares, accounting for 6.75% of the total shares.
Citadel Advisors LLC holds 1.90M shares, accounting for 6.03% of the total shares.
What are the top three shareholder types of Acrivon Therapeutics Inc?
The top three shareholder types of Acrivon Therapeutics Inc are:
RA Capital Management, LP
Chione, Ltd.
Blume-Jensen (Peter)
RA Capital Management, LP
Chione, Ltd.
Blume-Jensen (Peter)
How many institutions hold shares of Acrivon Therapeutics Inc (ACRV)?
As of 2025Q4, 134 institutions hold shares of Acrivon Therapeutics Inc, with a combined market value of approximately 17.71M, accounting for 69.32% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.37%.
What is the biggest source of revenue for Acrivon Therapeutics Inc?
In --, the -- business generated the highest revenue for Acrivon Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
